Basiliximab Maintenance in Ulcerative Colitis

Summary

Primary Objective Safety: assess the safety of basiliximab 40 mg, given every 4 weeks, in subjects with ulcerative colitis who completed previous basiliximab studies. Secondary Objectives: evaluate the efficacy and assess the immunogenicity of this multiple-dose maintenance regimen in this population

Timeline

Start

2007-07

Primary completion

2008-12

Completion

2008-12

Drugs

Indications